Article Text

PDF
Research protocol on early palliative care in patients with acute leukaemia after one relapse
  1. Cécile Barbaret1,2,
  2. Julien Berthiller3,4,
  3. Anne-Marie Schott Pethelaz3,4,
  4. Mauricette Michallet5,
  5. Gilles Salles5,
  6. Stéphane Sanchez2,6 and
  7. Marilène Filbet3,6
  1. 1 Palliative Care, Clinique de Soins Palliatifs et Coordination de Soins de Support, Centre Hospitalo-Universitaire de Grenoble, Grenoble, Auvergne-Rhône-Alpes, France
  2. 2 Medical department, Université Joseph Fourier, Grenoble, France
  3. 3 Clinical Research, Université Claude Bernard Lyon 1, HESPER unit EA 7425, Lyon, France
  4. 4 Clinical Research, Hospices Civils de Lyon, Pôle IMER, Lyon, France
  5. 5 Hematology, Service d’Hématologie du centre Hospitalier Lyon-Sud, Hospices Civils de Lyon, Lyon, France
  6. 6 Palliative Care, Centre de Soins Palliatifs, Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon, Lyon, France
  1. Correspondence to Dr Cécile Barbaret, Centre Hospitalo-Universitaire de Grenoble, 38700, Grenoble, France; cbarbaret{at}chu-grenoble.fr

Abstract

Objectives According to the American Society of Clinical Oncology palliative care referrals are made within the last 3 weeks of patients’ lives and most frequently when oncological treatments have ceased especially for patients with haematological malignancies. Recent publications indicate that patients with acute leukaemia are prone to symptoms, an indication for which a close collaboration between the patient’s haematologist and a palliative care team might result in improved symptom management. The object of this pilot study is to evaluate the feasibility of a clinical research trial to assess the effect of early palliative care in patients with acute leukaemia after one relapse.

Methods This project is a multicentre, non-blinded, randomised, controlled trial. Patients in group 1 will receive standard haematological care associated with palliative care (intervention group). Patients in group 2 will receive standard haematological care with palliative care only if requested by the haematologist (control group). In order to measure an accurate sample size, patients who participate will complete a standardised questionnaire to assess their quality of life, as well as their psychological and physical symptoms, before being randomised to one of two groups in a 1:1 ratio without stratified randomisation.

Results The aim of this study is to analyse causes of dropout, non-adherence and missing data in order to refine the protocol for the subsequent clinical research trial.

Conclusion The ultimate objective of this project is to develop collaboration between haematologists and palliative care teams in order to improve patients’ quality of life.

  • haematology
  • palliative care
  • collaboration
  • quality of life
  • symptom management
View Full Text

Statistics from Altmetric.com

Footnotes

  • Contributors Study concept and design by MF, CB, SS; drafting of the manuscript by CB, MF, SS; critical revision of the manuscript for important intellectual content by CB, LM, JB, A-MSP, GS, MM SS, MF.

  • Funding This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Ethics approval Institutional Review Board.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.